Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

(2020) Syed Faraz Ahmed et al.   Viruses-Basel

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

(2020) Alba Grifoni et al.   Cell Host & Microbe

SARS-CoV-2 Vaccines: Status Report

(2020) Fatima Amanat et al.   IMMUNITY

The convalescent sera option for containing COVID-19

(2020) Arturo Casadevall et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

(2020) Yeming Wang et al.   LANCET

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

A serological assay to detect SARS-CoV-2 seroconversion in humans

(2020) Fatima Amanat et al.   NATURE MEDICINE

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

(2020) Meng Yuan et al.   SCIENCE

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

(2020) Chek Meng Poh et al.   Nature Communications

Potential SARS-CoV-2 Preimmune IgM Epitopes

(2020) Velizar Shivarov et al.   Frontiers in Immunology

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

(2020) Kenneth H. Dinnon et al.   NATURE

Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma

(2019) Gayathri Vijayakumar et al.   EBioMedicine

Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels

(2017) Ren-qiang LIU et al.   Journal of Integrative Agriculture

Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions

(2012) Dmitriy Zamarin et al.   Future Microbiology

Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy

(2008) Adam Vigil et al.   MOLECULAR THERAPY